- Home
- TOYO vs TARA Comparison
TOYO vs TARA Comparison
Compare TOYO & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- TARA
- Stock Information
- Founded
- TOYO 2022
- TARA N/A
- Country
- TOYO Japan
- TARA United States
- Employees
- TOYO N/A
- TARA N/A
- Industry
- TOYO
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOYO
- TARA Health Care
- Exchange
- TOYO NYSE
- TARA Nasdaq
- Market Cap
- TOYO 142.6M
- TARA 158.2M
- IPO Year
- TOYO N/A
- TARA N/A
- Fundamental
- Price
- TOYO $2.94
- TARA $3.72
- Analyst Decision
- TOYO
- TARA Strong Buy
- Analyst Count
- TOYO 0
- TARA 3
- Target Price
- TOYO N/A
- TARA $22.67
- AVG Volume (30 Days)
- TOYO 22.7K
- TARA 270.4K
- Earning Date
- TOYO 03-07-2025
- TARA 03-12-2025
- Dividend Yield
- TOYO N/A
- TARA N/A
- EPS Growth
- TOYO N/A
- TARA N/A
- EPS
- TOYO 0.76
- TARA N/A
- Revenue
- TOYO $200,455,385.00
- TARA N/A
- Revenue This Year
- TOYO N/A
- TARA N/A
- Revenue Next Year
- TOYO N/A
- TARA N/A
- P/E Ratio
- TOYO $3.84
- TARA N/A
- Revenue Growth
- TOYO N/A
- TARA N/A
- 52 Week Low
- TOYO $1.36
- TARA $1.60
- 52 Week High
- TOYO $15.61
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- TARA 33.05
- Support Level
- TOYO N/A
- TARA $3.91
- Resistance Level
- TOYO N/A
- TARA $4.05
- Average True Range (ATR)
- TOYO 0.00
- TARA 0.29
- MACD
- TOYO 0.00
- TARA -0.07
- Stochastic Oscillator
- TOYO 0.00
- TARA 0.00
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).